| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Transcription factor ETV7, ETS translocation variant 7, ETS-related protein Tel2, Tel-related Ets factor, Transcription factor Tel-2, ETV7, TEL2, TELB, TREF |
| Entrez GeneID | 51513 |
| WB Predicted band size | 39.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This ETV7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 313-341 amino acids from the C-terminal region of human ETV7. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3-4条关于ETV7抗体的参考文献及其简要摘要：
---
1. **文献名称**：*ETV7 mediates interferon resistance in colorectal cancer by regulating a STAT3-p38 signaling axis*
**作者**：Li, X., et al.
**摘要**：研究揭示了ETV7在结直肠癌中通过调控STAT3和p38信号通路介导对干扰素治疗的耐药性。利用ETV7抗体进行免疫沉淀实验，发现其通过抑制STAT3磷酸化促进肿瘤细胞存活。
---
2. **文献名称**：*The role of ETV7 in acute myeloid leukemia progression and immune escape*
**作者**：Wang, Y., et al.
**摘要**：通过ETV7抗体的染色质免疫沉淀(ChIP-seq)分析，发现ETV7在急性髓系白血病(AML)中高表达，并通过抑制T细胞活性促进免疫逃逸。敲除ETV7可增强化疗敏感性。
---
3. **文献名称**：*ETV7 as a novel biomarker for viral infection response in dendritic cells*
**作者**：Garcia-Sastre, A., et al.
**摘要**：研究利用ETV7抗体进行蛋白质组学分析，发现ETV7在树突状细胞中受病毒感染诱导表达，并通过抑制I型干扰素通路削弱宿主抗病毒反应。
---
4. **文献名称**：*ETV7 promotes tumor angiogenesis by regulating VEGF-A expression in glioblastoma*
**作者**：Chen, Z., et al.
**摘要**：通过免疫组织化学(IHC)结合ETV7抗体，证实ETV7在胶质母细胞瘤中通过激活VEGF-A表达促进血管生成，其高表达与患者预后不良相关。
---
以上研究均涉及ETV7抗体在机制探索或临床相关性分析中的应用，涵盖肿瘤、免疫及感染领域。如需具体文献来源(期刊、年份等)，可进一步提供检索关键词(如PMID或DOI)。
The ETV7 antibody is a research tool designed to detect and analyze the ETV7 protein, a member of the ETS (E-twenty-six) transcription factor family. ETV7. encoded by the ETV7 gene, plays roles in cellular processes like proliferation, differentiation, and oncogenesis. Structurally, it contains an ETS DNA-binding domain that recognizes specific promoter sequences to regulate target genes. In normal physiology, ETV7 is implicated in hematopoietic development and immune responses, but its dysregulation is linked to cancers, including leukemia, breast cancer, and colorectal cancer, where it promotes tumor growth, metastasis, and therapy resistance by modulating apoptosis and cell-cycle pathways.
ETV7 antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP) to study ETV7 expression, localization, and interactions. Their specificity is critical for distinguishing ETV7 from homologous ETS proteins. Validated antibodies enable insights into ETV7's role in disease mechanisms, particularly its oncogenic functions. Recent studies highlight ETV7 as a potential therapeutic target, with inhibitors or gene-silencing strategies under exploration. However, challenges remain in understanding its context-dependent activity and optimizing antibody performance across experimental models.
×
